BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22919288)

  • 1. Prognostic assessment in patients with indolent B-cell lymphomas.
    Arcaini L; Rattotti S; Gotti M; Luminari S
    ScientificWorldJournal; 2012; 2012():107892. PubMed ID: 22919288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, pathology and treatment of non-follicular indolent lymphomas.
    Landgren O; Tilly H
    Leuk Lymphoma; 2008; 49 Suppl 1():35-42. PubMed ID: 18821431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodal and splenic marginal zone B cell lymphomas.
    Mollejo M; Camacho FI; Algara P; Ruiz-Ballesteros E; García JF; Piris MA
    Hematol Oncol; 2005; 23(3-4):108-18. PubMed ID: 16307458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors in low-grade non-Hodgkin lymphomas.
    Federico M; Molica S; Bellei M; Luminari S
    Curr Hematol Malig Rep; 2009 Oct; 4(4):202-10. PubMed ID: 20425409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies.
    Smyth E; Cheah CY; Seymour JF
    Cancer Treat Rev; 2023 Feb; 113():102510. PubMed ID: 36634434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A marginal zone pattern may be found in different varieties of non-Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma.
    Piris MA; Mollejo M; Campo E; Menárguez J; Flores T; Isaacson PG
    Histopathology; 1998 Sep; 33(3):230-9. PubMed ID: 9777389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection.
    Levine AM; Sadeghi S; Espina B; Tulpule A; Nathwani B
    Cancer; 2002 Mar; 94(5):1500-6. PubMed ID: 11920507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.
    Saleh K; Michot JM; Schernberg A; Lazarovici J; Chahine C; Danu A; Khalife-Saleh N; Rossignol J; Ghez D; Martin V; Mazeron R; Fermé C; Boros A; Ribrag V; Girinsky T
    Cancer Med; 2020 Jun; 9(11):3725-3732. PubMed ID: 32249547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia.
    Swerdlow SH
    Am J Clin Pathol; 2004 Dec; 122 Suppl():S98-109. PubMed ID: 15690646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.
    Tracy SI; Larson MC; Feldman AL; Maurer MJ; Novak AJ; Slager SL; Villasboas JC; Allmer C; Habermann TM; Farooq U; Syrbu S; Cerhan JR; Link BK
    Am J Hematol; 2019 Jun; 94(6):658-666. PubMed ID: 30916801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.
    Quintanilla-Martinez L; Sander B; Chan JK; Xerri L; Ott G; Campo E; Swerdlow SH
    Virchows Arch; 2016 Feb; 468(2):141-57. PubMed ID: 26416032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary nodal marginal zone lymphomas of splenic and MALT type.
    Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
    Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma.
    Monsálvez V; Montes-Moreno S; Artiga MJ; Rodríguez ME; Sanchez-Espiridion B; Lozano M; Fernández-de-Misa R; Rodríguez-Peralto JL; Piris MA; Ortíz-Romero PL
    Mod Pathol; 2013 Feb; 26(2):171-81. PubMed ID: 22936066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases.
    Camacho FI; Mollejo M; Mateo MS; Algara P; Navas C; Hernández JM; Santoja C; Solé F; Sánchez-Beato M; Piris MA
    Am J Surg Pathol; 2001 Oct; 25(10):1268-76. PubMed ID: 11688461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marginal zone-related neoplasms of splenic and nodal origin.
    Arcaini L; Paulli M; Boveri E; Magrini U; Lazzarino M
    Haematologica; 2003 Jan; 88(1):80-93. PubMed ID: 12551831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology of indolent B-cell neoplasms other than follicular lymphoma.
    Sakata S; Tsuyama N; Takeuchi K
    J Clin Exp Hematop; 2014; 54(1):11-22. PubMed ID: 24942942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
    Găman AM
    Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognosis of primary cutaneous lymphomas].
    Grange F; Bagot M
    Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):30-40. PubMed ID: 11937927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma.
    Munari E; Rinaldi M; Ambrosetti A; Bonifacio M; Bonalumi A; Chilosi M; Zamò A
    Virchows Arch; 2012 Dec; 461(6):677-85. PubMed ID: 23064660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.